Is IRD or MNKD more profitable?

MannKind has a net margin of -11.08% compared to Opus Genetics' net margin of -1,091.82%. MannKind's return on equity of -11.21% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Opus Genetics -1,091.82% -338.88% -150.13% MannKind -11.08% -11.21% -6.31%

Does the media refer more to IRD or MNKD?

In the previous week, Opus Genetics had 4 more articles in the media than MannKind. MarketBeat recorded 6 mentions for Opus Genetics and 2 mentions for MannKind. Opus Genetics' average media sentiment score of 1.26 beat MannKind's score of 1.19 indicating that Opus Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IRD or MLTX?

In the previous week, Opus Genetics had 4 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 6 mentions for Opus Genetics and 2 mentions for MoonLake Immunotherapeutics. Opus Genetics' average media sentiment score of 1.26 beat MoonLake Immunotherapeutics' score of 0.94 indicating that Opus Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRVS or IRD?

In the previous week, Corvus Pharmaceuticals had 4 more articles in the media than Opus Genetics. MarketBeat recorded 10 mentions for Corvus Pharmaceuticals and 6 mentions for Opus Genetics. Corvus Pharmaceuticals' average media sentiment score of 1.30 beat Opus Genetics' score of 1.26 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Opus Genetics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IRD or ODTX?

In the previous week, Odyssey Therapeutics had 5 more articles in the media than Opus Genetics. MarketBeat recorded 11 mentions for Odyssey Therapeutics and 6 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 1.26 beat Odyssey Therapeutics' score of 1.25 indicating that Opus Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Odyssey Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IRD or GLUE?

In the previous week, Monte Rosa Therapeutics had 15 more articles in the media than Opus Genetics. MarketBeat recorded 21 mentions for Monte Rosa Therapeutics and 6 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 1.26 beat Monte Rosa Therapeutics' score of 0.90 indicating that Opus Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Opus Genetics (IRD) Competitors

$3.69 -0.16 (-4.16%)

As of 08/28/2026 04:00 PM Eastern

Compare

IRD vs. MNKD, MLTX, CRVS, ODTX, and GLUE

Should you buy Opus Genetics stock or one of its competitors? Opus Genetics's main competitors and comparable companies include MannKind (MNKD), MoonLake Immunotherapeutics (MLTX), Corvus Pharmaceuticals (CRVS), Odyssey Therapeutics (ODTX), and Monte Rosa Therapeutics (GLUE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Opus Genetics compare to MannKind?

Opus Genetics (NASDAQ:IRD) and MannKind (NASDAQ:MNKD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Opus Genetics currently has a consensus price target of $10.69, indicating a potential upside of 189.76%. MannKind has a consensus price target of $9.22, indicating a potential upside of 133.39%. Given Opus Genetics' stronger consensus rating and higher probable upside, equities analysts clearly believe Opus Genetics is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

MannKind has higher revenue and earnings than Opus Genetics. MannKind is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	21.48	-$49.59M	-$1.35	N/A
MannKind	$348.97M	3.64	$5.86M	-$0.13	N/A

Opus Genetics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, MannKind has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

MannKind has a net margin of -11.08% compared to Opus Genetics' net margin of -1,091.82%. MannKind's return on equity of -11.21% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
MannKind	-11.08%	-11.21%	-6.31%

In the previous week, Opus Genetics had 4 more articles in the media than MannKind. MarketBeat recorded 6 mentions for Opus Genetics and 2 mentions for MannKind. Opus Genetics' average media sentiment score of 1.26 beat MannKind's score of 1.19 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Comparatively, 2.6% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Opus Genetics beats MannKind on 9 of the 17 factors compared between the two stocks.

How does Opus Genetics compare to MoonLake Immunotherapeutics?

Opus Genetics (NASDAQ:IRD) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

In the previous week, Opus Genetics had 4 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 6 mentions for Opus Genetics and 2 mentions for MoonLake Immunotherapeutics. Opus Genetics' average media sentiment score of 1.26 beat MoonLake Immunotherapeutics' score of 0.94 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 11.7% of Opus Genetics shares are held by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. MoonLake Immunotherapeutics' return on equity of -82.53% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

Opus Genetics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	21.48	-$49.59M	-$1.35	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

Opus Genetics presently has a consensus target price of $10.69, suggesting a potential upside of 189.76%. MoonLake Immunotherapeutics has a consensus target price of $24.57, suggesting a potential upside of 63.92%. Given Opus Genetics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Opus Genetics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

Opus Genetics has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Summary

Opus Genetics beats MoonLake Immunotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Opus Genetics compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by insiders. Comparatively, 11.7% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Corvus Pharmaceuticals has higher earnings, but lower revenue than Opus Genetics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
Opus Genetics	$14.20M	21.48	-$49.59M	-$1.35	N/A

Corvus Pharmaceuticals currently has a consensus target price of $33.33, indicating a potential upside of 135.40%. Opus Genetics has a consensus target price of $10.69, indicating a potential upside of 189.76%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts clearly believe Opus Genetics is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Corvus Pharmaceuticals had 4 more articles in the media than Opus Genetics. MarketBeat recorded 10 mentions for Corvus Pharmaceuticals and 6 mentions for Opus Genetics. Corvus Pharmaceuticals' average media sentiment score of 1.30 beat Opus Genetics' score of 1.26 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Opus Genetics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corvus Pharmaceuticals has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market.

Corvus Pharmaceuticals has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Corvus Pharmaceuticals' return on equity of -36.15% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
Opus Genetics	-1,091.82%	-338.88%	-150.13%

Summary

Corvus Pharmaceuticals beats Opus Genetics on 10 of the 15 factors compared between the two stocks.

How does Opus Genetics compare to Odyssey Therapeutics?

Opus Genetics (NASDAQ:IRD) and Odyssey Therapeutics (NASDAQ:ODTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Opus Genetics has higher revenue and earnings than Odyssey Therapeutics. Odyssey Therapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	21.48	-$49.59M	-$1.35	N/A
Odyssey Therapeutics	$99K	11,825.43	-$325.36M	-$6.77	N/A

Odyssey Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Odyssey Therapeutics' return on equity of 0.00% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
Odyssey Therapeutics	N/A	N/A	N/A

Opus Genetics currently has a consensus target price of $10.69, indicating a potential upside of 189.76%. Odyssey Therapeutics has a consensus target price of $35.75, indicating a potential upside of 46.76%. Given Opus Genetics' stronger consensus rating and higher possible upside, equities analysts plainly believe Opus Genetics is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

15.0% of Opus Genetics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Odyssey Therapeutics had 5 more articles in the media than Opus Genetics. MarketBeat recorded 11 mentions for Odyssey Therapeutics and 6 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 1.26 beat Odyssey Therapeutics' score of 1.25 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Odyssey Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Opus Genetics beats Odyssey Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Opus Genetics compare to Monte Rosa Therapeutics?

Opus Genetics (NASDAQ:IRD) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

In the previous week, Monte Rosa Therapeutics had 15 more articles in the media than Opus Genetics. MarketBeat recorded 21 mentions for Monte Rosa Therapeutics and 6 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 1.26 beat Monte Rosa Therapeutics' score of 0.90 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monte Rosa Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Opus Genetics presently has a consensus price target of $10.69, indicating a potential upside of 189.76%. Monte Rosa Therapeutics has a consensus price target of $28.50, indicating a potential upside of 113.00%. Given Opus Genetics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Opus Genetics is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Monte Rosa Therapeutics has a net margin of -560.85% compared to Opus Genetics' net margin of -1,091.82%. Monte Rosa Therapeutics' return on equity of -43.31% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Opus Genetics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market.

Monte Rosa Therapeutics has higher revenue and earnings than Opus Genetics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	21.48	-$49.59M	-$1.35	N/A
Monte Rosa Therapeutics	$123.67M	9.23	-$38.63M	-$1.76	N/A

Summary

Opus Genetics and Monte Rosa Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Opus Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRD vs. The Competition

Export

Metric	Opus Genetics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$304.97M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-2.73	11.62	273.16	25.45
Price / Sales	21.48	1,295.87	605.06	76.64
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	-23.06	16.53	12.98	6.14
Net Income	-$49.59M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-8.89%	-0.31%	0.13%	-0.80%
1 Month Performance	-3.91%	9.80%	7.08%	4.13%
1 Year Performance	202.46%	55.66%	24.67%	15.17%

Opus Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRD Opus Genetics	3.0239 of 5 stars	$3.69 -4.2%	$10.69 +189.8%	+202.5%	$304.97M	$14.20M	N/A	14	Positive News Options Volume
MNKD MannKind	2.4791 of 5 stars	$4.16 +2.2%	$9.22 +121.6%	-13.9%	$1.31B	$393.63M	N/A	400
MLTX MoonLake Immunotherapeutics	2.4702 of 5 stars	$15.56 +1.2%	$24.57 +57.9%	-73.1%	$1.31B	N/A	N/A	2
CRVS Corvus Pharmaceuticals	3.1306 of 5 stars	$14.56 +3.3%	$33.33 +128.9%	+146.7%	$1.22B	N/A	N/A	30	News Coverage Positive News
ODTX Odyssey Therapeutics	3.9215 of 5 stars	$26.23 +4.3%	$33.00 +25.8%	N/A	$1.21B	N/A	N/A	N/A	News Coverage Positive News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRD) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Opus Genetics (IRD) Competitors

IRD vs. MNKD, MLTX, CRVS, ODTX, and GLUE

How does Opus Genetics compare to MannKind?

Summary

How does Opus Genetics compare to MoonLake Immunotherapeutics?

Summary

How does Opus Genetics compare to Corvus Pharmaceuticals?

Summary

How does Opus Genetics compare to Odyssey Therapeutics?

Summary

How does Opus Genetics compare to Monte Rosa Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD vs. The Competition

Opus Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Opus Genetics (IRD) Competitors

IRD vs. MNKD, MLTX, CRVS, ODTX, and GLUE

How does Opus Genetics compare to MannKind?

Do analysts prefer IRD or MNKD?

Which has better valuation and earnings, IRD or MNKD?

Which has more risk & volatility, IRD or MNKD?

Is IRD or MNKD more profitable?

Does the media refer more to IRD or MNKD?

Do insiders & institutionals believe in IRD or MNKD?

Summary

How does Opus Genetics compare to MoonLake Immunotherapeutics?

Does the media refer more to IRD or MLTX?

Do insiders & institutionals hold more shares of IRD or MLTX?

Is IRD or MLTX more profitable?

Which has preferable earnings and valuation, IRD or MLTX?

Do analysts recommend IRD or MLTX?

Which has more volatility & risk, IRD or MLTX?

Summary

How does Opus Genetics compare to Corvus Pharmaceuticals?

Do institutionals & insiders have more ownership in CRVS or IRD?

Which has preferable valuation and earnings, CRVS or IRD?

Do analysts prefer CRVS or IRD?

Does the media favor CRVS or IRD?

Which has more volatility & risk, CRVS or IRD?

Is CRVS or IRD more profitable?

Summary

How does Opus Genetics compare to Odyssey Therapeutics?

Which has stronger earnings & valuation, IRD or ODTX?

Is IRD or ODTX more profitable?

Do analysts recommend IRD or ODTX?

Do institutionals and insiders believe in IRD or ODTX?

Does the media prefer IRD or ODTX?

Summary

How does Opus Genetics compare to Monte Rosa Therapeutics?

Does the media favor IRD or GLUE?

Do analysts prefer IRD or GLUE?

Is IRD or GLUE more profitable?

Do insiders & institutionals believe in IRD or GLUE?

Which has more volatility & risk, IRD or GLUE?

Which has stronger earnings & valuation, IRD or GLUE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD vs. The Competition

Opus Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools